{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:11:26Z","timestamp":1792145486746,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.09.010","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:06:12Z","timestamp":1726751172000},"page":"30-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2703-0867","authenticated-orcid":false,"given":"Jacob","family":"O'Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Nazareth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Wat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W","family":"Southern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-6502","authenticated-orcid":false,"given":"Freddy","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.09.010_bib0001","unstructured":"Naito Y., Charman S., Duckers J., Clarke S. UK Cystic Fibrosis Registry: 2022 Annual Data Report. 2023 September 2023. (UK Cystic Fibrosis Registry). Cystic Fibrosis Trust."},{"key":"10.1016\/j.jcf.2024.09.010_bib0002","article-title":"A survey assessing the impact of COVID-19 and elexacaftor\/tezacaftor\/ifavacaftor on both physical and mental health in adults with cystic fibrosis [Note]","author":"Sakon","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.09.010_bib0003","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease [Article]","volume":"80","author":"Martin","year":"2021","journal-title":"Respir Med Res"},{"issue":"4","key":"10.1016\/j.jcf.2024.09.010_bib0004","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor: multidimensional assessment of neuropsychological side effects and physical and mental health outcomes in adolescents and adults [Article]","volume":"165","author":"Graziano","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2024.09.010_bib0005","unstructured":"MHRA. The yellow card scheme - reporting adverse drug reactions. Medicines and Healthcare products Regulatory Agency; 2022. Available from: https:\/\/yellowcard.mhra.gov.uk\/."},{"issue":"12","key":"10.1016\/j.jcf.2024.09.010_bib0006","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/ppul.26116","article-title":"Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis [Letter]","volume":"57","author":"Lyman","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2024.09.010_bib0007","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and psychopathology in cystic fibrosis: a case report","volume":"61","author":"Tindell","year":"2020","journal-title":"Psychosomatics"},{"issue":"6","key":"10.1016\/j.jcf.2024.09.010_bib0008","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cystic Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.09.010_bib0009","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2017.05.008","article-title":"Worsening anxiety and depression after initiation of lumacaftor\/ivacaftor combination therapy in adolescent females with cystic fibrosis","volume":"16","author":"McKinzie","year":"2017","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.09.010_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor therapy","author":"Arslan","year":"2023","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.09.010_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27100","article-title":"Mental health, sleep, and respiratory health after initiating elexacaftor\/tezacaftor\/ivacaftor treatment in children with cystic fibrosis [Article]","author":"Pham","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2024.09.010_bib0012","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.23cr03649","article-title":"A case of elexacaftor\/tezacaftor\/ivacaftor\u2013 induced depressive symptoms and suicidal thoughts [Article]","volume":"26","author":"Godier","year":"2024","journal-title":"Prim Care Companion CNS Disord"},{"issue":"6","key":"10.1016\/j.jcf.2024.09.010_bib0013","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/YIC.0000000000000475","article-title":"Neuropsychiatric symptoms in a patient under cystic fibrosis transmembrane conductance regulator modulators treatment: a case report [Article]","volume":"38","author":"Andreu","year":"2023","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.jcf.2024.09.010_bib0014","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/ppul.26527","article-title":"Positive and negative impacts of elexacaftor\/tezacaftor\/ivacaftor: healthcare providers' observations across US centers [Article]","volume":"58","author":"Bathgate","year":"2023","journal-title":"Pediatr Pulmonol."},{"issue":"6","key":"10.1016\/j.jcf.2024.09.010_bib0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MCP.0000000000001014","article-title":"Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort [Review]","volume":"29","author":"Vanelzakker","year":"2023","journal-title":"Curr Opin Pulm Med"},{"issue":"12","key":"10.1016\/j.jcf.2024.09.010_bib0016","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.jcf.2024.09.010_bib0017","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients [Article]","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jcf.2024.09.010_bib0018","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health [Article]","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2024.09.010_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.19686","article-title":"Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic","volume":"3","author":"Ettman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jcf.2024.09.010_bib0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:11:20Z","timestamp":1738275080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324017806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324017806"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}